MMJ Bioscience, which specializes in medical cannabis products, has filed a request with the U.S. Food and Drug Administration (FDA) to open Phase 2 clinical trials evaluating the company’s THC/CBD pharmaceutical compounds as possible treatments for symptoms of multiple sclerosis (MS).
THC refers to the tetrahydrocannabinol compound, part of the cannabis plant. CBD stands for cannabidiol, the compound that is thought to have the most healing potential.
“Our goal is to conduct clinical research and generate safety and efficacy data on our medication to support a comprehensive review by the FDA and approval as a prescription medicine that will deliver consistency and quality for multiple sclerosis patients,” Timothy Moynahan, chairman of MMJ, said in a press release.
Bianca Weinstock-Guttman, executive director of the New York State Multiple Sclerosis Consortium, is set to lead a study exploring the potential therapeutic applications of medical cannabis in patients with